Cannabis Strategic Ventures, Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

Cannabis Strategic Ventures, Inc. (OTC Pink: NUGS) announces the signing of a definitive agreement to acquire the Fitamins CBD brand. Under the terms of the agreement, Fitamins will be distributing their vitamin and hemp derived CBD formulations through their network of 600+ wholesalers catered to the Asian-American market. Also today, CannabisNewsWire released a report on the company detailing how Cannabis Strategic Ventures this morning announced that its wholly-owned subsidiary, Pure Applied Sciences, has commenced production of its Halo Filters. To view the full press release, visit: http://cnw.fm/5g7pN. Additionally, NUGS was featured in an article on how the cannabidiol (CBD) market has arguably been cannabis’ best success to date, as CBD-based products continue to work their way into society in a variety of forms, ranging from health and beauty products to pet applications.

Cannabis Strategic Ventures, Inc. (OTC: NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $1.69, up 9.74%, on 43,320 volume with 123 trades. The average volume for the last 60 days is 24,433 and the stock's 52-week low/high is $0.031/$7.13.

Recent News

• Cannabis Strategic acquires Fitamins CBD brand and distribution network
• CannabisNewsBreaks – Cannabis Strategic Ventures, Inc. (NUGS) Subsidiary Starts Production of Halo Filters
• Cannabidiol (CBD) Product Sales Exponentially Increase As Mainstream Consumer Adoption Rates Continue to Jump

Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF)

The QualityStocks Daily Newsletter would like to spotlight Phivida Holdings Inc. (PHVAF).

WeedMD Inc. (TSX-V:WMD) (OTC:WDDMF) (FSE:4WE) (“WeedMD”) and Phivida Holdings Inc. (CSE: VIDA) (OTC.PHVAF) ("Phivida") are pleased to announce the signing of a final definitive joint venture agreement (“Agreement”) to develop and operate Cannabis Beverages Inc. (“CanBev”) at WeedMD’s state-of-the-art greenhouse facility in Strathroy, Ontario.

Headquartered in Vancouver, Canada, with operations offices in southern California, Phivida Holdings Inc. (CSE: VIDA) (OTCQX: OTCQX) is a premium food and beverage company that develops CBD-infused functional foods, beverages and supplements poised for global distribution. All products in the Phivida label are infused with organic, hemp-derived cannabinoids into a variety of premium foods, beverages and clinical products for everyday health. Phivida is guided by a team of Fortune 500-caliber executives focused on a new strategic portfolio of products and brands, comprehensive consumer research, new product and brand development, improved visual identity and packaging design, and a strong distribution strategy.

The company’s motto – “Celebrating Health and Wellness, in Harmony™” – underscores Phivida’s mission to lead the alternative health care sector as the benchmark standard in premium CBD-infused functional beverages and tinctures. To execute this goal, Phivida is taking advantage of positive legislative developments in the United States and has defined an elevated national route-to-market strategy across the U.S. where small regional distributors will be now be replaced with large national distributors.

Management

Phivida’s management team includes president and CEO Jim Bailey, former president of Red Bull Canada and global chief marketing officer for Merrell Outdoors; Chief Marketing Officer Michael Cornwell, former chief marketing officer for Samsung New Zealand and the former director of marketing for Red Bull Canada; and Doug Campbell, former director of sales for Red Bull North America, who as Phivida’s chief commercial officer is tasked with driving new sales revenue growth.

Publicly traded on the Canadian Securities Exchange (CSE.VIDA) and recently graduated to the OTCQX Best Market in the USA (OTCQX.PHVAF), the company’s strong balance sheet carries CAD$15.7 million with no debt or loans with less than 60 million shares outstanding and the company is now well-capitalized to fun major mainstream distribution with a solid structure poised for long-term growth.

The Science

Using encapsulation technology, Phivida uses full spectrum CBD-hemp oil (rich in naturally occurring phytocannabinoids) converted into a water-soluble delivery format, which enhances delivery and absorption of the cannabinoids into the human body – up to an estimated tenfold.

Encapsulated CBD is infused into functional beverages, food and supplements containing a proprietary blend of phytonutraceuticals studied to target a range of health and wellness conditions. Phivida tests every product for microbials, heavy metals, pesticides, residual solvents, terpenes, and potency to guarantee less than 0.3 percent THC (tetrahydrocannabinol, the chemical compound in cannabis responsible for a euphoric high) is present.

Regulations

Federally legal under the 2014 Farm Bill, CBD from Hemp Oil is a rapid growth market across the USA. When derived from marijuana, CBD remains a schedule one controlled substances, giving hemp derived CBD oil infused products a competitive advantage on regulations. On June 28, 2018, the U.S. Senate passed the Agriculture Improvement Act of 2018 (i.e. the “Farm Bill), lifting the USA Industrial Hemp laws to an agricultural commodity status and effectively removed hemp from the controlled substance list.

Earlier this year, another milestone court ruling also provided significant regulatory support for the US CBD-Hemp sector. In February 2018, the Supreme Court preceded over the HIA (Hemp Industry Association) vs. DEA (Drug Enforcement Agency) in a class-action suit concerning the issue of CBD extracted from hemp, and the legality of industrial hemp. In the final ruling the Supreme Court unequivocally determined that – when produced domestically under the Farm Bill – hemp (and its derivatives) are not a controlled substance.

The Supreme Court ruling also found the Farm Bill (as it relates to hemp) “pre-empts” the Controlled Substances Act. Congress has since exempted Farm Bill hemp from the Controlled Substances Act (CSA) giving the Farm Bill primary jurisdiction over the governance of the CBD-Hemp Oil industry in the USA.

The DEA further conceded it does not “seek to control cannabinoids,” and that only marijuana derived cannabinoids are governed under the Controlled Substances Act. In May of 2018, the DEA issued a formal directive to all federal agencies (e.g. US Customs and Border Patrol) stating that cannabinoids are not controlled substances unless derived from marijuana, and that the “mere presence of cannabinoids” in any product or derivative does not render it a controlled substance. The Supreme Court ruling also resulted in the mediation of a settlement in what is now the third successful HIA vs. DEA suit in over a decade.

In Canada, the Senate approval of Bill C-45 legalized the production, distribution and use of recreation cannabis – with edibles to be added in 2019. The bill will officially become law as of October 17, 2018, creating a legal framework for the production, distribution, sale and possession of cannabis across Canada including cannabinoid-infused beverages.

3 Wholly Owned Subsidiaries

• Phivida Organics Inc. offers professional-grade, wholesale, whole plant hemp oil extracts made from 100-percent certified organic hemp stalk. Phivida’s hemp oil extracts are CO2-extracted under quality assurance/clinical standards and are third-party lab tested to assure only pharmaceutical grade, cGMP certified, full-spectrum products are produced and available for sale. Phivida Organics produces hemp oil extracts that deliver nano-encapsulated cannabinoids in water soluble formulations designed to be absorbed up to 10 times faster than other oils, providing up to 400 percent bioavailability. Phivida Hemp Oil Vida+ extract products are available now online at www.Phivida.com.
• Phivida Nutrition blends the best of nature into CBD-infused lifestyle branded beverages including a variety of CBD infused iced teas and CBD infused flavored waters.
• Phivida Enhanced – Under the VIDA brand, CBD-infused tinctures, capsules and other supplement products are distributed to alternative health care clinics across the USA.

WeedMD-Phivida

Phivida has signed a binding letter of intent to joint venture WeedMD Inc. (TSX-V: WMD) (OTC:WDDMF) (FSE:4WE), a Health Canada federally licensed producer and distributor of medical cannabis, to form a joint venture focused on cannabis-infused beverages. The new joint-venture company, Cannabis Beverages Inc. (“CanBev”), plans to develop a production facility at WeedMD’s state-of-the-art greenhouse facility in Strathroy, Ontario, Canada. CanBev is on track to build and operate the first cannabis-infused beverage production facilities in Canada. The joint venture will focus on manufacturing, marketing and distribution of cannabinoid-infused beverages for the legalized medical and adult-use cannabis markets.

Management from both WeedMD and Phivida are collaborating on design and engineering strategies and site evaluations on a 610,000-square-foot, state-of-the art facility in Strathroy for the development of CanBev. As an emerging certified food grade production plant, the Strathroy facility is an ideal location and comes is equipped with extensive production infrastructure, including 50,000 sq. ft. of food production and packaging area, cold storage, loading docks, and adequate space to expand for future growth.

Strategic Agreements

Phivida Organics has also entered into an agreement to carry out a pharmacokinetic (PK) study on its hemp-derived, nanoencapsulated CBD with Artelo Biosciences Inc. at the University of Nottingham, School of Medicine at the Royal Derby Hospital, England. The study will test encapsulated-CBD on healthy volunteers and measure how fast and how much CBD enters the blood stream after oral consumption with each of the different formulations developed by Phivida Organics.

Phivida has also activated distribution agreements with Asayake Inc. to become one of the first federally approved CBD-infused food and supplement brands in Japan. With first mover status achieved, Phivida now markets to an underserved, yet highly informed population of 127 million patients and practitioners. The supplement market in Japan is estimated at US$10 billion with the overall functional foods market at US$21 billion. The Asia-Pacific region is the fastest growing market for natural plant-based supplements. Phivida now plans to prepare a formal application to Japan’s Consumer Affairs Agency to register the company’s CBD-infused functional food and beverage products for approval under the country’s Food with Functional Claims regime. The functional beverage market in Japan is estimated at US$10.35 billion with a CAGR of 2.5 percent (2015-2025).

Further Information

www.Phivida.com
+1 (844) 744-6646 (ext. #2)
IR@Phivida.com

Phivida Holdings Inc. (PHVAF), closed the day's trading session at $0.538, up 7.60%, on 20,870 volume with 26 trades. The average volume for the last 60 days is 26,914 and the stock's 52-week low/high is $0.05/$1.80.

Recent News

• WeedMD and Phivida Sign Definitive Agreement on Cannabis Beverages Inc.
• NetworkNewsBreaks – Why Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) is “One to Watch”
• Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) to Launch OKI Brand CBD-Infused Products in 3Q2018, Signs Agreement for Access to 2,400 Stores

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF) reported its financial and operational results for the second quarter of fiscal 2018, ended June 30th, 2018. These filings are available for review on the Company's SEDAR profile at www.sedar.com.

The Green Organic Dutchman (TSX: TGOD) (OTCQX: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $4.1205, up 7.87%, on 346,599 volume with 807 trades. The average volume for the last 60 days is 245,005 and the stock's 52-week low/high is $2.784/$7.565.

Recent News

• The Green Organic Dutchman Reports Q2 Results
• CannabisNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTC: TGODF) Enters Agreement with E-Commerce Leader Shopify Inc. (NYSE: SHOP) (TSX: SHOP)
• The Green Organic Dutchman Selects Shopify for Ecommerce Solution

WhereverTV Broadcasting Corp. (OTCQB: TVTV)

The QualityStocks Daily Newsletter would like to spotlight WhereverTV Broadcasting Corp. (TVTV).

WhereverTV (OTCQB:TVTV), (the “Company”) announced CEO, Edward D. Ciofani’s return interview with Everett Jolly, host of Uptick Newswire’s “Stock Day” Podcast.

WhereverTV Broadcasting Corp. (OTC: TVTV) is a next-generation OTT (Over-the-top) television subscription service that manages live-stream broadcast programming rights across multiple devices, geographies and languages, providing viewers with personalized service that is truly “wherever” they may be watching TV.

WhereverTV’s patented Interactive Program Guide (IPG) technology currently handles over 125 live channels that are broadcasted securely over the Internet to any Internet-enabled device anywhere in the world. Many of the company’s channels are the same as those broadcasted by traditional cable and satellite companies. For example, the World News Now package includes One America News, RT News (Russia Today), Bloomberg TV, CBN News and EuroNews Live — the latter provides pan-European coverage in 350 million households in 155 countries. Other channel packages include Choice TV (a wide variety of popular options for the family), Spanish TV, Faith TV and Morocco TV, providing current genre-specific subscriptions for news, faith, drama, sports, movie, reality and children’s programming.

WhereverTV’s free app works with iOS and Android devices to cover the spectrum of mobile consumer needs, as well as with personal desktop or laptop computers through its over the top (OTT) platform. The platform delivers channels, shows and events to SmartTVs and digital media receivers that include Google Chromecast, AppleTV, Amazon Fire TV, iPhone, iPad, Android Smartphone and TabletPCs, with DVR recording functionality slated for future development.

The company, based in Fort Myers, Florida, was developed in 2007 as a solution to its founder’s frustration with the complexities of trying to stream English speaking content while abroad.  As the live-streaming market has developed over the decade since then, WhereverTV has gained recognition as a pioneer in next-generation content delivery systems.

WhereverTV’s strategy is to increase revenue-generating subscriptions worldwide through the acquisition of content that is desirable to consumers and deliverable anywhere a device can connect to the Internet. Prepaid accounts will be accessed through the cloud, and the IPG technology will allow users to make their viewing choices. The company has developed two separate divisions, one for worldwide distribution and one for Latin American distribution.

In 2017, the company acquired Digital Rodeo, LLC, a Tennessee limited liability company that delivers a rich mixture of music and videos from independent country artists, current arrests and legacy artists, as well as similar Florida-based companies Digital RodeoTV, LLC (Name changed to WhereverTV Country in 2018), Digital CrossTV, Inc., Digital PopTV, Inc., and Digital RockTV, Inc.

“WhereverTV is transitioning from a development to operational company and in doing so we have refined our 2018 business model,” CEO Edward D. Ciofani stated. “Our business model calls for content acquisition from around the world, exclusive content development, Major Marketing Alliances, similar to the announced Google Chromecast for Latin America and major marketing initiatives including social media marketing. … There are a lot of content providers (channel providers) around the world that offer a uniquely diversified perspective of cultures, travel and lifestyle content.”

As an increasing number of people “Cord-Cutters” no longer subscribe to the traditional cable or satellite distribution but rather a simpler lower cost means of watching content. The streaming OTT industry is expected to grow to $62 billion by 2020 — nearly triple its revenues in 2015, per Goldman Small Cap Research. Future Market Insights estimated the North America OTT market alone at $16.29 billion in 2017 with a CAGR of 17.4 percent through 2028. The arrival of 5G technology this year has the potential to accelerate the pace.

WhereverTV Broadcasting Corp. (TVTV), closed the day's trading session at $0.0732, up 4.57%, on 14,290 volume with 4 trades. The average volume for the last 60 days is 34,020 and the stock's 52-week low/high is $0.041/$0.46.

Recent News

• CEO Edward D. Ciofani of WhereverTV Returns to Discuss Company Updates with Everett Jolly on Uptick Newswire’s “Stock Day” Podcast
• NetworkNewsWire Releases Exclusive Audio Interview with WhereverTV Broadcasting Corp. (OTCQB: TVTV)
• WhereverTV files Patent Infringement against Comcast Corporation

Zenosense, Inc. (OTCQB: ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO).

MIDS Cardiac™, a handheld diagnostic device for cardiac emergency triage being developed by Zenosense, Inc. (OTCQB: ZENO), could prove to be revolutionary in the diagnostic process. Incorporating the patented MIDS technology, which is predicated on the nano-magnetic detection of assay beads and has demonstrated detection of low enough assay bead numbers to be suitable for high sensitivity cardiac biomarker tests, shows real potential to be able to ensure accurate results, delivered at a fraction of the time required by large and expensive laboratory analyzers and right at the point of care, according to an article by Zacks Small Cap Research (http://nnw.fm/u0w7A) and recent quantitative results released by Zenosense.

Zenosense, Inc. (OTCQB: ZENO) (the “Company”) is a healthcare technology developer that participates in transformational, disruptive medical diagnostic projects; particularly handheld devices used at the Point of Care which are displacing slow and expensive laboratory tests.

Zenosense is primarily focused on the development and commercialization of MIDS Cardiac™ through the Company’s joint venture ownership in MIDS Medical Limited (“MML”). MIDS Cardiac is in development as a cost-effective, handheld Point of Care (“POC”) diagnostic device and disposable test strip for the early, rapid detection of suspected acute myocardial infarction (“AMI”, or “heart attack”).

Identification of very low levels of cardiac markers can significantly accelerate critical triage, diagnosis, treatment and disposition of patients reporting chest pain. Cardiac troponin is well documented as the preferred biomarker for diagnosis of AMI, with evidence continuing to demonstrate that high sensitivity troponin is the most powerful prognostic biomarker for the assessment of cardiovascular risk in the general population. However, highly sensitive troponin assays are currently available only on state of the art, central laboratory analyzers. These analyzers are extremely expensive, not generally available at the POC and slow to turnaround results (typically 60 minutes) when time is critical.

True, high-sensitivity devices are not available in smaller handheld devices at the POC, where they are most needed. This is because the optical detection systems generally used in central laboratory analyzers cannot be effectively miniaturized.

MIDS Cardiac uses the patented MIDS technology platform, exclusively available to MML. Instead of using conventional optical detection, MIDS can detect and quantify assay beads nano-magnetically. This means it can be incorporated in a small device expected to achieve highly sensitive detection levels, which can support true high sensitivity cardiac biomarker tests in emergency settings, at the POC.

Harnessing world-class expertise, the MML laboratory is located at the prestigious Sci-Tech Daresbury campus in the U.K., internationally recognized for leading-edge, scientific research and commercial development. MML has the sole rights to the MIDS technology platform, which is protected by patent applications already granted in China and the USA, and applications now in the national phase in all other key geographic areas.

MIDS Cardiac aims to provide a single troponin I or T test within 3 minutes and three panel assay (additional cardiac biomarkers) on a disposable test strip within 8 minutes, using a hand-held device costing a fraction of the price of laboratory analyzers.

MIDS Cardiac should only require a pin prick of blood for a single assay test carried out on an easy-to-use, disposable microfluidic test strip. MIDS Cardiac is being designed to be operated quickly by minimally trained personnel, producing a simple to interpret result in emergency settings, even in the back of an ambulance.

Initial testing of the electronic and microfluidic components of the MIDS Cardiac “Hybrid Strip” system was completed in November 2017. The Hybrid Strip system used for development testing aims to replicate as closely as possible a fully integrated Lab on Chip MIDS test strip set-up. Development testing was conducted on both the assembled hybrid unit and its electronic and microfluidic components separately, focusing mainly on the electronics of the magnetic sensing system.

Testing revealed that a variety of brands and sizes of commercially available assay beads could be magnetically detected in very low quantities, including samples of beads that were previously undetectable. In several instances, the current “limit of detection” appeared to already be at or near to the range advised by MML’s assay consultants as suitable for a high sensitivity troponin assay.

Dr. Nasser Djennati, MML’s Managing Director and Chief Scientific Officer, said; “These results come in at the very high end of detection expectations, even at this Hybrid Strip stage. As we move forward into true Lab on Chip construction, I expect detection levels to improve further still.”

Cardiovascular disease is the leading cause of death in the western world, accounting for more than 17 million deaths in Europe and the United States alone. Nearly 20 million patients each year visit an emergency room with reports of chest pain, with hundreds of millions spent on unnecessary admissions to the hospital. Zenosense Inc. is confident MIDS Cardiac will deliver unparalleled levels of accuracy, speed, reliability, ease of use and cost savings, making it the future device of choice for hospitals, emergency rooms, medical practitioners, paramedics and in low-resource settings.

The MIDS technology is also seen as having a far wider application, with the platform being capable of performing Point of Care immunoassay tests for a vast array of common healthcare concerns, a market projected to be worth $23.7 billion per year worldwide by 2019. The medical testing market as a whole is projected to be worth $53.34 billion by 2021. Zenosense believes the MIDS technology could be the most significant advance in diagnostic testing services in decades.

Zenosense, Inc. (ZENO), closed the day's trading session at $0.38, up 4.11%, on 131,262 volume with 31 trades. The average volume for the last 60 days is 259,664 and the stock's 52-week low/high is $0.15/$0.895.

Recent News

• MIDS Cardiac by Zenosense, Inc. (ZENO): A Heart Attack Diagnostic Revolution?
• NetworkNewsBreaks – Zenosense, Inc. (ZENO) Transforming Modern Cardiac Diagnostics
• Zenosense, Inc. (ZENO) Aims to Revolutionize Cardiac Diagnostics Market

Sharing Services, Inc. (OTC: SHRV)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services, Inc. (SHRV).

Sharing Services, Inc. (OTC: SHRV) has appointed network marketing veteran Keith Halls to the positions of president and COO of its Elepreneur, LLC subsidiary. Moving forward, he will be tasked with leading the company’s global growth (http://nnw.fm/3RcZp). SHRV has also appointed Global Payroll Gateway (GPG) as its payment processor and e-commerce financial partner (http://nnw.fm/ciXS5). That company is seen as an important asset as SHRV expands internationally.

Sharing Services, Inc. (OTC: SHRV), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRV has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

• A growing international network of home-based entrepreneurs, called “Elepreneurs”
• Growing selection of health and wellness products dedicated to elevating the well-being of all people
• Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
• Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
• Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
• Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services, Inc.’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders –  Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services, Inc., and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services, Inc., at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services, Inc. (SHRV), closed the day's trading session at $0.34, up 3.03%, on 23,758 volume with 9 trades. The average volume for the last 60 days is 20,630 and the stock's 52-week low/high is $0.125/$0.95.

Recent News

• Sharing Services, Inc. (SHRV) Names Network Marketing Veteran Keith Halls as President, COO of Elepreneur Subsidiary
• Sharing Services, Inc. Names Award-Winning Network Marketer Keith Halls as President and Chief Operating Officer of Elepreneur
• Sharing Services Inc. (SHRV) Selects Global Payroll Gateway as New Merchant Processor, E-Commerce Partner

CytoDyn Inc. (OTCQB: CYDY)

The QualityStocks Daily Newsletter would like to spotlight CytoDyn Inc. (CYDY).

CytoDyn Inc. (OTCQB:CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications in the treatment of HIV, cancer, and inflammatory conditions, announces that Michael A. Klump, President and Chief Executive Officer of Argonne Capital Group, has joined the CytoDyn Board of Directors. Mr. Klump is a significant investor in CytoDyn and brings extensive financing and mergers and acquisition expertise to the CytoDyn Board.

CytoDyn Inc. (OTCQB: CYDY) is a biotechnology company focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. The company’s pipeline includes its lead product, PRO 140 for multiple indications among which are human immunodeficiency virus (HIV), graft-versus-host disease (GvHD), colon cancer, and multiple sclerosis (MS), each in various stages of development. CytoDyn first approval is focused on HIV indications for two different HIV populations.

PRO 140 is a humanized monoclonal antibody directed at CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 works by blocking the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5.

CytoDyn has completed one pivotal phase 3 clinical trials of PRO 140 use in combination with current drugs for population that has limited treatment options. PRO 140 is also currently in another phase 3 (investigative trial) for a second approval for another HIV population. HIV continues to be a major global public health issue. There is no cure for the disease that has claimed more than 35 million lives to date, according to the World Health Organization (“WHO”). In 2017, 940,000 people around the world died from HIV-related causes. There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected during that same year. The WHO estimates there were 21.7 million people globally receiving antiretroviral therapy (“ART”) in 2017.

HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. As the virus destroys and impairs the function of immune cells, infected individuals gradually become immunodeficient which results in increased susceptibility to a wide range of infections, cancers and other diseases that people with healthy immune systems can fight off. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can take from 2 to 15 years to develop depending on the individual.

PRO 140 functions by blocking the HIV co-receptor CCR5, a molecular portal HIV uses to enter T-cells, thus preventing the HIV virus from entering the cell. CCR5 is a protein located on the surface of white blood cells that normally serves as a receptor for chemicals that attract immune cells to the site of inflammation. Clinical trials to date indicate PRO 140 does not interfere with these normal CCR5 functions. Results from phase 1 and phase 2 human clinical trials have shown PRO 140 significantly reduces viral burden in people infected with HIV. Importantly, in a recent phase 2b clinical trial, PRO 140 demonstrated it can allow a subset of R5 strain of HIV population to replace their current HIV regimen (Highly Active Antiretroviral Therapy or “HAART.”) by a simple sub-cutaneous self-injectable dose of PRO 140 which is administered once a week. Some of those patients have received PRO 140 as their only therapy for almost four years.

The PRO 140 antibody appears to be a powerful antiviral agent with hardly any side effects, toxicity. More than 500 patients have used PRO 140 in clinical trial and no resistance has ever been developed in any patients including patients in monotherapy of PRO 140 for almost four years.

PRO 140, which is taken as an easy-to-use, weekly, subcutaneous self-administered dose, has almost no side effects or toxicity with no report of any serious adverse event related to PRO 140 in more than 500 patients in eight different clinical trial.

As we indicated earlier patients given PRO 140 showed no drug resistance on monotherapy for some almost four years while 76% of HAART patients developed a resistance to some portion of the lifetime drug regimen. Patient compliance with HAART is also the main reason why only 35% of HIV patients in US reporting complete viral load (VL) suppression which is VL<50 cp/mL.

In addition to its research into the powerful potential of PRO 140 for use in HIV patients, CytoDyn is pursuing PRO 140 as a therapeutic anti-viral agent in other non-HIV indications that could benefit from PRO 140’s ability to block CCR5. These immunologic indications include new reactions to cancer, transplantation rejection, autoimmune diseases and chronic inflammation such as Multiple Sclerosis. The company sees the significant potential for multiple pipeline opportunities for PRO 140.

The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. The company is also investigating PRO 140 in animal models of cancer progression and autoimmunity with positive results and has published its animal study results in GvHD in peer-reviewed journal.

CytoDyn president and CEO Nader Z. Pourhassan, Ph.D. joined the company in 2008 and is credited for purchasing PRO 140 from Progenics in 2012 and has taken a new path to approval for the product. He is the co-inventor of monotherapy path for PRO 140. He has taken PRO 140 development from phase 2 to Completed successful phase 3 in about four years. He now has more than 10 years of drug development experience and has overseen the rapid clinical development of PRO 140 as a therapy for HIV into two phase 3 for two different indications. He also initiated PRO 140 first immunological indication in GvHD (currently in phase 2). He is also involved in preclinical and clinical development of PRO 140 in additional immunological indications.?Dr. Pourhassan, who has more than 20 years of business development experience, has led CytoDyn’s capital market activities since joining the company in 2008. He received his Bachelor of Science from Utah State University, Master of Science from Brigham Young University, and his Ph.D. in Mechanical Engineering from the University of Utah and is the author of three books.

CytoDyn Inc. (CYDY), closed the day's trading session at $0.5011, up 2.27%, on 249,089 volume with 38 trades. The average volume for the last 60 days is 330,329 and the stock's 52-week low/high is $0.40/$0.836.

Recent News

• CytoDyn Announces Strong Preclinical Results Using PRO 140 in Human Colon Carcinoma
• CytoDyn Appoints Michael A. Klump to Board of Directors
• CytoDyn Inc. (CYDY) Reports HIV Single Agent Therapy Progress Following Improved Response Rate at Higher Dose

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is the developer of a disruptive drug delivery platform, DehydraTECH™, that the company out-licenses to entities aiming to deliver healthier ingestion methods of cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. To view the full article, visit: http://nnw.fm/rAx5Q. Also today, NetworkNewsWire released a report on the company detailing how LXRP is one of the companies looking at alternative solutions to the scientifically established harmful health effects of smoking, using fatty acids to make a pleasing, fast, effective delivery system for nicotine and cannabidiol (CBD).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.74, up 2.96%, on 259,563 volume with 297 trades. The average volume for the last 60 days is 229,867 and the stock's 52-week low/high is $0.322/$2.54.

Recent News

• NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Continues to Demonstrate Versatility
• Big Businesses Look for Healthier Alternatives to Smoking for Drug Delivery
• Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Human Clinical Study on TurboCBD Capsules Corroborates Earlier DehydraTECH Test Results

Auscrete Corp. (OTC: ASCK)

The QualityStocks Daily Newsletter would like to spotlight Auscrete Corp. (ASCK).

In a world that’s keenly aware of the impact that every action has on the environment, businesses in all types of industries are committing to operate as sustainably as possible. Auscrete Corp. (OTC: ASCK) offers a unique path to environmental responsibility and economic efficiency. The building materials manufacturing company is focused on leading the way in the “green” movement.

Auscrete Corp. (OTC: ASCK) is a building products manufacturer of environmentally-friendly, energy-efficient housing and commercial structures using a lightweight hybrid concrete material developed through a proprietary technology. Auscrete’s unique process produces a medium that is cost-efficient, extremely soundproof, offers high insulation values, requires very low maintenance, won’t burn, non-toxic, highly resistant to insects and mold, and resists damage from hurricane forces and earth tremors. It’s a more affordable, energy-efficient “green” construction material that can be utilized for building residential housing and commercial structures.

Affordable homes are increasingly becoming more difficult to purchase in the U.S. with the median price of a new home consistently rising while wages stay stagnant in many areas and mortgage rates rise. The average price of new homes sold in the U.S. in 2017 was nearly $385,000, according to Statista. The homeownership rate in the U.S. has been in decline since 2004, the report states, and now amounts to a little more than 64 percent of Americans.

Auscrete’s lightweight concrete product is described as an aerated concrete material following infusion of a specially designed foaming agent during manufacture. This technology enables the product to have millions of minuscule air bubble “aggregates” introduced and evenly distributed throughout the cast sections, which creates a unique, lightweight product without compromising strength or structural integrity. Each hybrid panel also incorporates a distinctive XPS insulation amalgamation that guarantees greater comfort in a wide range of climatic conditions and a reduction in heating and cooling costs. The final product is a light and strong concrete panel with an extremely high insulation value, as well as excellent fire resistance and sound-proofing qualities.

Auscrete’s product also offers a high strength-to-weight ratio, allowing architects and engineers to develop new design and construction concepts that take advantage of the product’s reduced weight, which is nearly half that of normal concrete. Each panel can be cast in large sections, a common size being 16-feet by 8-feet, for easier transportation and faster construction on site. Savings are enhanced, not only by the energy efficiency of each panel, but through the use of mass production techniques. Auscrete estimates the company can produce a ready-to-move-in turnkey house for around $100 per square foot, which is significantly less than the 2017 median list price of $148 per square foot in the U.S., according to a report by Zillow.

Auscrete is constructing its flagship, 10-acre facility in Goldendale, Washington, on initially 5 acres the company recently purchased with the option to purchase another 5 adjacent acres. This new campus will ultimately comprise of 6 buildings, including 3 production buildings of 25,000 sq. ft. with each production buildings’ capacity of 100 homes annually, giving this flagship facility the ability to produce 300 homes or equivalent commercial structures per year.

During this construction phase, Auscrete has leased a commercial building in Goldendale. The facility will be used as a temporary headquarters and will also serve as a refurbishing station for production equipment the company has developed and used in its prior production plant. John Sprovieri, CEO and founder of Auscrete Corporation, is at the helm of the company with Mike Young serving as vice president of internal operations and Otto Paulette controlling the in-house mechanical services.

Auscrete’s Investor Relations Director, Lee Odom said, “The company’s construction process has already attracted interest from many developers, contractors and builders, some with large tracts of land looking to make available, significant numbers of Affordable Homes throughout the Country. Additionally, there have been significant commercial projects offered including 300 room destination hotel resorts, correctional facilities, a shopping complex, and a court house along with a flood of inquiries from people who are looking for more affordable building options”.

“This could really launch the commercial aspect for?ASCK, apart from residential home production which so many investors are not yet aware of,” Odom said. “A strong combination of both will lead?ASCK?to better performance through all business cycles, thus continuing to enhance the shareholder values, which is always the ultimate goal of Auscrete Corporation.”

Auscrete Corp. (ASCK), closed the day's trading session at $0.0508, up 0.20%, on 21,800 volume with 3 trades. The average volume for the last 60 days is 121,289,728 and the stock's 52-week low/high is $0.0001/$0.10.

Recent News

• Environment and Economy are Focuses of Auscrete Corp.’s (ASCK) Distinctive Concrete Product
• NetworkNewsBreaks – Auscrete Corp. (ASCK) Setting Up New Production Plant in Ontario with Canadian Investment Group
• Auscrete Corporation (ASCK) Discusses California Fires in Exclusive NNW Audio Interview

Global Payout, Inc. (OTC: GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE).

Global Payout Inc. (OTCPink:GOHE) is pleased to announce that it has successfully signed and begun implementing one of San Diego’s premier dispensaries, The Healing Center (THC), and is expected to go live with MTrac by the end of the week.

Global Payout, Inc. (OTC: GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout’s fully configurable “banking-in-a-box” web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today’s banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout’s management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and “high-risk” market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and “high-risk” enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions.

Global Payout, Inc. (GOHE), closed the day's trading session at $0.01152, off by 1.54%, on 4,611,674 volume with 116 trades. The average volume for the last 60 days is 5,182,145 and the stock's 52-week low/high is $0.0099/$0.16.

Recent News

• MTrac Signs The Healing Center to MTrac Payment Platform
• Specific Therapeutic Benefits of Cannabidiol (CBD) Validated by FDA
• CannabisNewsBreaks – Global Payout, Inc. (GOHE) Unveils Restructuring Plan

Earth Science Tech, Inc. (OTC: ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (OTC: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields; medical devices; and research and development, today shares it has initiated the up-listing process through the OTCQB in anticipation of approval of its Form 10 Registration Statement. Also today, CannabisNewsWire released a report on the company detailing how ETST is testing in Canada and Brazil a diverse mix of cannabidiol (CBD) formulations, including a superfood formula (http://cnw.fm/9tTZ1). It is also conducting pre-launch lab studies of a medical device scheduled to be marketed internationally (http://cnw.fm/ej7NG).

Earth Science Tech, Inc. (OTC: ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

• Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
• Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
• KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.70, off by 8.38%, on 10,041 volume with 12 trades. The average volume for the last 60 days is 10,296 and the stock's 52-week low/high is $0.324/$1.62.

Recent News

• Earth Science Tech, Inc. Initiates Up-Listing Process in Anticipation of Form 10 Registration Statement Approval
• Earth Science Tech, Inc. (ETST) Pursues Multi-National Development of CBD Formulations, Hemp-Based Superfood and Home Testing Kit
• CannabisNewsBreaks – Earth Science Tech, Inc. (ETST) is a Chocolatier of Full Spectrum, Flavored Cannabinoid Products

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), and Asterion Cannabis Inc. ("Asterion") announce that they have signed an agreement (the "Licensing Agreement"), whereby Asterion has granted to PreveCeutical a worldwide licence to use, manufacture, distribute and sell three Health Canada approved natural health products (the "Products").

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.0271, off by 6.55%, on 191,778 volume with 27 trades. The average volume for the last 60 days is 613,769 and the stock's 52-week low/high is $0.002/$0.20.

Recent News

• PreveCeutical Signs Agreement with Asterion Cannabis Inc. to License Natural Health Products and Engages Monster Media, LLC to Provide Investor Relations Services
• PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is Named for its Attention to Preventative Health Care
• CannabisNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Unveils Medicinal Cannabis Division’s First Product Development Program

DPW Holdings, Inc. (NYSE American: DPW)

The QualityStocks Daily Newsletter would like to spotlight DPW Holdings, Inc. (DPW).

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), and Asterion Cannabis Inc. ("Asterion") announce that they have signed an agreement (the "Licensing Agreement"), whereby Asterion has granted to PreveCeutical a worldwide licence to use, manufacture, distribute and sell three Health Canada approved natural health products (the "Products").

DPW Holdings, Inc. (NYSE American: DPW), is a diverse holding company pursuing a growth strategy of  acquiring undervalued assets with disruptive technologies with a global impact.

The company invests in diverse industries within the commercial, defense/aerospace, industrial, communication, medical, crypto-mining, hospitality, textile, and corporate investment/lending sectors. DPW has evolved and grown from being a leader in advanced power products. Through its subsidiaries, the company continues to be a leader and supplier of innovative technologies, advanced design and development services, and state-of-the-art power products and solutions.

Through its wholly owned Coolisys Technologies, Inc. subsidiary, DPW is committed to offering world-class technology-based solutions for critical applications and lifesaving services that are primarily driven by innovation. Coolisys targets to the defense, aerospace, naval, homeland security, medical, telecom, datacom and industrial markets. Its growth strategy centers on core markets that are characterized by “high barriers to entry” and require specialized products and services not likely to be commoditized. Through a portfolio of companies, Coolisys is engaged in developing and manufacturing advanced switching power products and power solutions that utilize a customized digital power management and resonant topology to attain:

• The highest efficiency and highest density power converters and inverters
• Specialized complex airborne high-frequency, radio frequency (RF), and microwave detector-log video amplifiers (DLVA)
• Very high-frequency filters
• Naval power conversion and distribution equipment

Coolisys offers its technology and services through three primary groups: the Power Solutions Group (PSG), the Defense and Aerospace Solutions Group (DSG), and the Advanced Service Industries (ASI) Group. Coolisys manages five divisions:

• Digital Power Corporation, a leader in providing power electronics technology that is based in northern California.
• Digital Power Limited dba Gresham Power Ltd, a designer and manufacturer of power distribution systems primarily for Naval use that is based in Salisbury, UK.
• Microphase Corporation, a designer and manufacturer of microwave electronics technology that is based in Shelton, Connecticut.
• Power-Plus Technical Distributors, a value-added distributor that is based in Sonora, California.
• Enertec Systems, a developer and manufacturer of specialized advanced electronic systems for the defense and aerospace sectors that is based in Karmiel, Israel.

DPW’s portfolio of wholly owned subsidiaries also includes Digital Power Lending, LLC (DPL), a California private lending company operating under Financial Lender’s License ##60DBO-77905. DPL is dedicated to strategically providing capital to small and middle-size businesses for an equity interest in addition to loan fees and interest. DPL provides secured and unsecured debt financing for public and private companies. These loans will typically have a six to 12-month maturity and range from $250,000-$5 million. DPL is active in bridge loans, receivable financing, inter company loans and micro loans. DPL will work with a network of company owned ATMs (terminals) in California, which will help utilize its CA Finance Lending License and enable the company to offer micro loans of up to $500 or less.

Management has over 50 years of Wall Street experience of investing in, and building companies. DPL’s desire is to bring world-class companies lending opportunities while allowing main street investors to participate. Deal flow and organization comes from an extensive network of investment bankers, business brokers, family offices, and institutional clients enabling DPL to engage and fund the most compelling companies from Silicon Valley to Wall Street.

To date, DPL has funded over $19 million in loans. Since inception, DPL has internally funded over $15 million to DPW’s portfolio companies and wholly owned subsidiaries. As for companies outside DPW, DPL has lent over $4 million in commercial and real estate loans. DPL has funded INVO Bioscience, Medovex, Parallax, Alzamend Neuro, as well as hospitality clients, such as Guilia DTLA and Prep Kitchens.

Another subsidiary wholly owned by DPW is Super Crypto Mining, Inc., a cloud computing service that provides shared and managed computing resources optimized for various block chain mining solutions. Based in Newport Beach, California, Super Crypto Mining leverages its engineering expertise and existing locations to create cryptocurrency mining facilities throughout the world. The company owns and maintains the computing resources and sells access to their use. The established mining is on the Top 3 crypto-currencies with the goal of having 10,000 miners deployed in 2018. Super Crypto Mining endeavors to leverage its engineering expertise and existing global facilities (high-security defense business locations) to secure mining farms. Super Crypto Mining is a rapidly growing organization that recently strategically secured 25 mega watts to power the company’s mining farm. For crypto currency mining, locations with inexpensive power and secure capacity are minimal and hence costly. Having such a location allows the company to grow its mining business to more than 20,000 mining machines. Super Crypto Mining continues to purchase mining machines and explore opportunities to expand its services into other related areas including mining farm real estate investments, mining machine development, and mainstream blockchain projects.

DPW additionally has beneficiary ownership in MTIX International, Inc., the parent company of MTIX, Ltd. and I.AM, Inc.

MTIX was acquired by Avalanche International aka MTIX International, Inc., in August 2017 and offers “green technology” that uses a proprietary laser process to enhance the surface of textiles. This process reduces water usage by approximately 75 percent, reduces greenhouse gases by approximately 90 percent, and reduces chemical use by approximately 95 percent.

I.AM, acquired in May 2018, owns and operates hospitality offerings that include four Prep Kitchen brand restaurants and Giulia DTLA.

Utilizing a shareholder-centric approach to compensation, DPW has formulated the following 10-year objectives:

• Achieve compounded annual revenue growth of 25-35%
• Achieve compounded annual net Income growth of 5%
• Achieve positive unrestricted free cash flow by the end of 2019

DPW is led by a seasoned team of successful business professionals and entrepreneurs. The company is headquartered in Newport Beach, California.

DPW Holdings, Inc. (DPW), closed the day's trading session at $0.41, off by 14.58%, on 2,808,950 volume with 3,554 trades. The average volume for the last 60 days is 1,912,418 and the stock's 52-week low/high is $0.4205/$5.95.

Recent News

• PreveCeutical Signs Agreement with Asterion Cannabis Inc. to License Natural Health Products and Engages Monster Media, LLC to Provide Investor Relations Services
• DPW Holdings’ Microphase Corporation Secures $2.0 Million Supplemental Order from Top-Tier U.S. Defense Contractor
• CryptoNewsBreaks – Why DPW Holdings, Inc. (NYSE American: DPW) is “One to Watch”

Hiku Brands Co. Ltd. (CSE: HIKU) (OTC: DJACF)

The QualityStocks Daily Newsletter would like to spotlight Hiku Brands Co. Ltd. (DJACF).

Headquartered in British Columbia’s picturesque Okanagan Valley, Hiku Brands Co. Ltd. (CSE: HIKU) (OTC: DJACF) iis a premium cannabis lifestyle brand growing high-quality handcrafted cannabis flower. Hiku’s wholly owned subsidiary is a licensed producer of cannabis under the ACMPR that has requested its Pre-Sales License Inspection, the last step prior to receiving a license to sell cannabis under the ACMPR. Hiku’s Dominion Facility is a state-of-the-art ACMPR licensed production facility capable of producing approximately 660 kg year of dried cannabis flower. Hiku’s second facility, a 22,580 sq ft warehouse, “the FUTURE LAB”, is targeting its Phase 1 completion by Q2 2018 and once the facility is fully built-out utilizing an industry leading multi-tier system powered by LED lighting provided by Fluence BioEngineering, Hiku’s annual production capacity is expected to be in excess of 5,000 kgs. Hiku was founded by the proven entrepreneurial team that started SAXX Underwear®.

On December 21, 2017, Hiku and TS Brandco Holdings Inc. (“Tokyo Smoke”) announced that they have entered into a binding Letter of Intent (“LOI”) to merger the two companies and create a uniquely positioned cannabis company combining a best-in-class craft cannabis producer with an award-winning lifestyle brand and retail-focused cannabis company. It is anticipated that the combined company resulting from the merger will use the name “Hiku Brands Company Ltd.” (“Hiku”) to refer to the brand house containing premium cannabis brands DOJA, Tokyo Smoke, and Van der Pop.

Hiku recently closed on a $10 million strategic equity investment from Aphria Inc. (“Aphria”) (TSX:APH and US OTC: APHQF) to expand their product offering ahead of the recreational market.

Upon completion of the merger, Hiku will have a robust cash position of approximately $31 million, which it plans to invest in expanding its cannabis production capacity, growing its retail footprint, and adding select brands to its portfolio through highly strategic and complementary acquisitions.

About Tokyo Smoke
Founded in 2015 by Alan and Lorne Gertner, Tokyo Smoke is an award-winning cannabis lifestyle brand that brings sophistication and design to the fast-growing industry. With immersive experiences and design-first, non-dispensary retail spaces selling coffee, cannabis accessories and design products, the brand has six locations in Canada, with plans to expand nationwide. Recently named “Brand of the Year” at the Canadian Cannabis Awards, Tokyo Smoke has showcased excellence in brand storytelling, and has developed an international reputation as the go-to destination for engaging content offerings within the industry. With the acquisition of fellow designer cannabis brand Van der Pop, and by partnering with Aphria Inc. (TSX: APH and US OTC: APHQF) and WeedMD (TSXV: WMD), Tokyo Smoke continues to be the leading Canadian brand in the cannabis space.

About Hiku
Hiku is focused on handcrafted cannabis production, immersive retail experiences, and building a portfolio of iconic, engaging cannabis lifestyle brands. Hiku is differentiated as the only Canadian craft cannabis producer with a significant national retail footprint and a growing brand house including premium cannabis lifestyle brands DOJA, Tokyo Smoke, and Van der Pop.

Hiku’s wholly owned subsidiary, DOJA Cannabis Ltd., is a federally licensed producer pursuant to the ACMPR, owning two production facilities in the heart of British Columbia’s Okanagan Valley. The company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

Hiku Brands Co. Ltd. (DJACF), closed the day's trading session at $1.473, up 30.41%, on 747,092 volume with 566 trades. The average volume for the last 60 days is 248,471 and the stock's 52-week low/high is $0.20/$3.8799.

Recent News

• Hiku Brands, New Merger Agreement with Canopy Growth and Potential Synergies
• 11 Licensed Producers that Signed Retail Supply Agreements in Alberta
• Hiku Brands Provides Update on Alberta Retail Storefronts